Paul Doghramji, MD, FAAFP

Drs Paul Doghramji and Leslie Citrome share approaches to communicate with patients and increase awareness of insomnia disorder

Leslie Citrome, MD, MPH, comments on long-term data for daridorexant, suvorexant, and lemborexant.

Experts discuss daridorexant efficacy and safety data, and dosing considerations and what to communicate with patients when using daridorexant for insomnia.

Drs Paul Doghramji and Leslie Citrome provide an overview of dual orexin receptor antagonists (DORAs), suvorexant, lemborexant, and daridorexant, in treatment of insomnia disorder.

Drs Paul Doghramji and Leslie Citrome discuss the sleep and wakefulness signals and pathways that contribute to insomnia.

Drs Paul Doghramji and Leslie Citrome review the use of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) to assess treatment efficacy.

Experts discuss treatment for patients experiencing insomnia in conjunction with other health conditions.

Drs Paul Doghramji and Leslie Citrome review prescription drugs and over-the-counter remedies for treating insomnia.

Experts highlight cognitive behavioral therapy for insomnia (CBTI) and sleep hygiene as nonpharmacological approaches to the treatment of insomnia.

Drs Paul Doghramji and Leslie Citrome discuss daytime sleepiness and other symptoms of insomnia and their impact on quality of life.

Experts review the co-occurrence of insomnia with other medical conditions and discuss risks and triggers that lead to insomnia, such as age and psychiatric conditions.

Drs Paul Doghramji and Leslie Citrome provide an overview of the diagnosis and prevalence of insomnia.